Evaluate the Efficacy and Safety of Co-administration of JW0104+C2402 in Patients With Hypertension and Dyslipidemia
NCT ID: NCT06643130
Last Updated: 2025-09-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE3
162 participants
INTERVENTIONAL
2024-12-02
2026-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Clinical Trial to Evaluate the Efficacy and Safety of Co-administration of JW0108+C2407 in Patients With Dyslipidemia
NCT06955104
To Evaluate the Efficacy and Safety in Patients With Dyslipidemia and Hypertension
NCT05331014
Safety and Efficacy Study of JTT-705 in Combination With Simvastatin 40 mg in Patients With Low High-Density Lipoprotein (HDL) Levels
NCT00688558
Phase 3 Study to Evaluate the Efficacy and Safety of Co-administrated AD-2021 and AD-2022
NCT06448962
Clinical Trial to Evaluate the Efficacy and Safety of DW1125 and DW1125A
NCT05970679
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
JW0104+C2402
JW0104+C2402, 8 weeks, QD (Quaque Die)
JW0104+C2402
For 8 weeks(PO (Per Oral), QD)
JW0104+C2403
JW0104+C2403, 8 weeks, QD
JW0104+C2403
For 8 weeks(PO, QD)
C2402
C2402, 8 weeks, QD
C2402
For 8 weeks(PO, QD)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
JW0104+C2402
For 8 weeks(PO (Per Oral), QD)
JW0104+C2403
For 8 weeks(PO, QD)
C2402
For 8 weeks(PO, QD)
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
19 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
JW Pharmaceutical
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Minjung Kim
Role: STUDY_CHAIR
JW Pharmaceutical
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Gangdong Sacred Heart Hospital
Seoul, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
JW24301
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.